Australia - inglés - Department of Health (Therapeutic Goods Administration)

servier laboratories australia pty ltd - gliclazide -

Singapur - inglés - HSA (Health Sciences Authority)

pharmaforte singapore pte ltd - gliclazide - tablet - 80 mg - gliclazide 80 mg

Singapur - inglés - HSA (Health Sciences Authority)

pharmaforte singapore pte ltd - gliclazide - tablet, extended release - 30.0mg - gliclazide 30.0mg

Malasia - inglés - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaforte (malaysia) sdn. bhd. - gliclazide -

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

medreich plc - gliclazide - oral tablet - 40mg

Australia - inglés - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: sodium acetate; magnesium stearate; lactose monohydrate; silicon dioxide; mannitol; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; mannitol; silicon dioxide; hypromellose; magnesium stearate; sodium acetate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: magnesium stearate; silicon dioxide; lactose monohydrate; sodium acetate; mannitol; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; mannitol; sodium acetate; silicon dioxide; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; sodium acetate; silicon dioxide; mannitol; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.